Stockreport

Bioblast Pharma Announces Sale of its Trehalose Clinical Development Programs to Seelos Therapeutics

BIO BLAST PHARMA LTD ORDINARY  (ORPN) 
Last bio blast pharma ltd ordinary earnings: 5/26 04:15 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.bioblastpharma.com/investor-overview-0
PDF Unconditional payment of $3.5 million Contingent payment of up to additional $17 million plus royaltiesSeelos to receive rights also to the Trehalose for Sanfilippo Synd [Read more]